Abstract 1724
Background
In 2018 the role of clinical nurse specialist (CNS) was implemented in an ambulatory setting at our cancer research center in Italy. CNSs received specific training before taking on their new role. Although measuring the impact of CNSs is vital to support decision-making on the development and implementation of advanced nursing roles, the identification of indicators reflecting their impact on clinical practice remains one of the most challenging nursing research issues, mainly because of the complexity of the contributors who determine patient and organizational outcomes.
Methods
The study evaluated indicators measuring the implementation process and the impact of the CNS role one year after its introduction. Indicators for the former were: CNS interface mapping in disease pathways, participation rate of CNS in multidisciplinary team (MDT) meetings, and number of training hours/CNS on specific cancers. Indicators for the latter were: patient satisfaction with CNS (survey), compliance with priority criteria for waiting times for the first visit, total number of documented CNS-patient communications (i.e. first nursing interviews with new patients, phone interviews); and number of improvement projects to which CNSs contributed.
Results
One year after CNS introduction, pathway mapping was 100%; MDT meeting participation 95%; training hours 40.5/CNS vs. defined standard of 30 hours. 83.2% of interviewed patients were very satisfied with CNSs. An average of 27 patient interviews and 126 phone interviews per month were performed. Improvements to the instruments used for patient agenda management were made, positively impacting compliance (+13%) with waiting time criteria.
Conclusions
CNSs were successfully introduced into all identified disease pathways and played an active role within the MDTs. Although there are data in literature indicating optimal CNS staffing for specific cancers, there are no previous Italian experiences that can be used for comparative purposes. We need to better clarify how disease characteristics and the number of new patients influence CNS staffing in our specific organizational care context, which obviously differs from that of other countries. Measuring CNS activities and outcomes would also help to optimize CNS core activities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Istituto Scientifico Romagnolo per lo Studio e per la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract